Peptide Sports Medicine Reviews: Four 2026 Papers, One Verdict on the Evidence

Research literature · 17 September 2026

Four peptide sports medicine reviews published in peer-reviewed journals during 2026 have now assessed the same family of compounds — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu among them — and they arrive at a consistent description of the evidence base: most of it is animal research, and the human studies that exist are few and mostly poorly controlled. The most recent and most systematic of the four was published in The American Journal of Sports Medicine on 11 August 2026 by a team at UCLA.

What the four peptide sports medicine reviews covered

These are not vendor white papers or blog summaries. They are four separate reviews, in four journals, by different author groups, published across eight months of 2026. Read together they are the clearest picture currently available of what the published literature on these compounds actually contains.

The headline finding: 67% animal models

The August scoping review searched PubMed using combinations of six peptide names against musculoskeletal tissue terms — bone, fracture, muscle, tendon, ligament, meniscus and cartilage — following PRISMA reporting guidelines. Two reviewers screened papers independently with a third as tiebreaker. Its central result, stated in the abstract: 67% of identified publications used preclinical animal models, most commonly rats.

In those animal models the authors describe “promising but variable effects” on tendon, muscle, bone and ligament healing, with each compound showing distinct mechanisms. That is a real finding, and it is the reason these compounds attract interest in the first place. It is also not the same thing as evidence of benefit in people.

UCLA’s own write-up of the paper puts the number of screened studies at 565. That figure appears in the university’s press material rather than in the published abstract, so we cite it to the press release rather than to the journal.

What the human studies actually measured

This is the part most summaries skip, and it is the most useful detail in the paper. Human clinical studies were, in the authors’ words, “limited to a handful of investigations, most lacking robust controls or rigorous study designs.” The human data were heterogeneous and showed modest improvements at best for metabolic bone health and degenerative knee pain.

Note the mismatch. These compounds are widely discussed for tendon repair, muscle recovery and post-injury healing. The human evidence the review located was about bone metabolism and knee osteoarthritis pain — different indications entirely. The authors also record significant heterogeneity in dosing and route of administration across studies, which is what makes pooling such results unreliable even in principle.

Risks the reviews flagged

The reviews are not neutral on safety. The August paper records that MK-677 was associated with significant risks including congestive heart failure, and its conclusion names documented risks including cardiovascular complications and metabolic dysfunction such as insulin resistance. The authors state that, given the lack of robust efficacy and safety data, these supplements “should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care.”

The April 2026 review in Sports Medicine covers a wider list — AOD-9604, BPC-157, CJC-1295, FS-344, GHK-Cu, ipamorelin, MOTS-C, sermorelin, SS-31 (elamipretide), tesamorelin, thymosin beta-4 and TB-500 — and draws a line between approved peptide drugs that went through a full safety and efficacy review and a parallel market of unapproved compounds that it describes as operating largely outside regulatory oversight. The May 2026 review in JBJS Reviews, which searched PubMed/MEDLINE, Embase and Web of Science across January 2020 to August 2025, summarises the situation as clinical adoption having outpaced high-quality evidence and regulatory consensus.

One further methodological point, raised by co-author Kushagra Tewari in UCLA’s interview: one of the larger BPC-157 studies was conducted by a group holding a financial interest in the compound. Declared or not, that is a factor readers should weigh when a single study is cited as decisive.

What this does not mean

It does not mean these molecules are inert or that the animal work is worthless — preclinical research is how drug development starts, and the reviews describe genuine mechanistic findings. It does not mean every peptide is unstudied; several named above are approved drugs with substantial trial evidence behind them for specific indications. And a scoping review reports on the literature it locates: the August paper searched PubMed only, which is a stated limitation.

What it does mean is that anyone citing “the research” on these six compounds for musculoskeletal use is, on the current record, mostly citing rodent studies. That is worth knowing before reading any further claim.

Frequently asked questions

Is a scoping review the same as a systematic review?

No. A scoping review maps what literature exists on a topic and how it is distributed; a systematic review asks a narrower question and formally appraises and often pools the results. The August paper followed PRISMA reporting guidance and used independent duplicate screening, but it is described by its authors as a scoping review, which is why its central output is a description of the evidence base rather than a pooled effect size.

Does 67% animal studies mean 33% were human trials?

No, and this is an easy misreading. The review reports that 67% of identified publications used preclinical animal models. The remainder is not specified as human trials — it would also include in-vitro work, reviews and other non-animal publication types. The authors separately describe human clinical studies as limited to a handful of investigations.

Why do these reviews appear in sports medicine journals?

Because that is where the clinical questions are arriving. All four reviews frame the issue around patients and athletes asking clinicians about compounds marketed for injury recovery and performance, which is why they assess musculoskeletal indications specifically rather than every proposed use.

Are these the same compounds FDA has been considering for compounding?

There is overlap but they are separate processes. BPC-157, TB-500 and others appear both in this literature and in the FDA compounding discussions, but an advisory committee vote on compounding eligibility is a regulatory question, not a finding about clinical efficacy. We cover that track separately.

Informational only — not medical advice. This article summarises published research literature and does not recommend, endorse or provide guidance on the use of any compound. Consult a qualified healthcare professional. Intended for readers 21 and over.